Key terms
About PTN
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PTN news
Apr 11
11:20am ET
Biotech Alert: Searches spiking for these stocks today
Apr 08
11:05am ET
Buy Rating Affirmed for Palatin Technologies Following Successful Phase 3 Trial of PL9643 for Dry Eye Disease
Apr 08
7:33am ET
Palatin presents results from Phase 3 PL9643 MELODY-1 trial
Mar 14
4:21pm ET
Palatin files to sell 1.92M shares of common stock for holders
Feb 29
7:56am ET
Maintained Buy Rating on Palatin Technologies Amid Promising Clinical Results and Future Prospects
Feb 28
12:10pm ET
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Palatin Technologies (PTN) and G1 Therapeutics (GTHX)
Feb 28
10:10am ET
Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN) and Opko Health (OPK)
Feb 28
9:59am ET
Palatin price target lowered to $17 from $70 at H.C. Wainwright
Feb 28
7:33am ET
Palatin announces results from PL9643 MELODY-1 pivotal Phase 3 clinical trial
Feb 16
10:25am ET
Buy Rating Affirmed for Palatin Technologies Amid Promising Clinical Trials and Robust Financial Position
Feb 16
7:36am ET
Buy Rating Affirmed on Palatin Technologies for Promising Pipeline and Strategic Market Positioning
Feb 15
11:45am ET
Optimistic Buy Rating for Palatin Technologies Backed by Strong Clinical Pipeline and Strategic Initiatives
Feb 15
7:36am ET
Palatin reports Q2 EPS (56c), consensus (20c)
Feb 05
7:37am ET
Palatin announced database lock for Phase 3 trial of dry eye disease candidate
Feb 05
7:37am ET
Palatin announced database lock for Phase 3 trial of dry eye disease candidate
Feb 01
11:24am ET
Biotech Alert: Searches spiking for these stocks today
Jan 31
10:56am ET
Biotech Alert: Searches spiking for these stocks today
Jan 30
8:07am ET
Palatin sells 1.83M shares at $5.46 in registered direct offering
No recent press releases are available for PTN
PTN Financials
Key terms
Ad Feedback
PTN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PTN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
